Abstracts tagged "immunology"

Abstract Number: 0995 • ACR Convergence 2021
Innate Immune Tolerance Attenuates Zymosan-Induced Arthritis, Inflammatory Gene Expression and Synovial Neutrophil Infiltration
Richard Bell, Chao Yang, Caroline Brauner, Upneet Sohki, Rouxi Yuan, Bikash Mishra, Mahesh Bachu and Lionel Ivashkiv, Hospital for Special Surgery, New York, NY
Background/Purpose: Zymosan (Zym) induces arthritis through TLR2- and Dectin-1-activated NK-κB signaling and inflammatory myeloid cell infiltration into the synovium of the injected joint. Innate immune…
Abstract Number: 1774 • ACR Convergence 2021
Blood-based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients
Michelle Mulder¹, Xuehui He², Juul van den Reek², Paulo Urbano², Charlotte Kaffa², Xinhui Wang³, Bram van Cranenbroek², Esther van Rijssen², Frank van den Hoogen⁴, Irma Joosten², Wynand Alkema⁵, Elke de Jong², Ruben Smeets², Mark Wenink⁶ and Hans Koenen², ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Radboud University Medical Center, Nijmegen, Netherlands, ³University of Luxembourg, Belvaux, Luxembourg, ⁴Sint Maartenskliniek, Ubbergen, Netherlands, ⁵Hanze University of Applied Sciences, Groningen, Netherlands, ⁶Sint Maartenskliniek, Malden, Netherlands
Background/Purpose: Early detection of psoriatic arthritis (PsA) in psoriasis (Pso) patients is crucial for timely treatment and prevention of structural joint damage. We aimed to…
Abstract Number: 0184 • ACR Convergence 2021
Phase III, Randomized Trial Comparing Clinical Outcomes Between Patients with Moderate-to-severe Chronic Plaque Psoriasis Receiving Adalimumab Reference Product (RP) Continuously versus Those Who Switched Between BI 695501 and Adalimumab RP
Alan Menter¹, Dorothy McCabe², Benjamin Lang³, Jennifer Schaible⁴ and Sravan Kumar Eduru⁵, ¹Baylor Scott & White, Dallas, TX, ²Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, ³Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁴Boehringer Ingelheim Pharma GmbH & Co. KG, Boberach, Germany, ⁵(Formerly at) Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
Background/Purpose: BI 695501 is a FDA-approved biosimilar to adalimumab RP (AbbVie), and is approved in seven indications, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis,…
Abstract Number: 1004 • ACR Convergence 2021
Manipulation of B7 Family Member Expression Demonstrates Synovial Macrophage Plasticity and Possible Future Targets for Treatment of Rheumatoid Arthritis
Annabelle Small¹, Katie Williams², Antonio Ferrante³, Malcolm Smith², Susanna Proudman⁴, Helen Weedon¹ and Mihir Wechalekar⁵, ¹Flinders University, Bedford Park, Australia, ²Flinders University, Adelaide, Australia, ³SA Pathology; University of Adelaide, Adelaide, Australia, ⁴University of Adelaide, Medindie, Australia, ⁵Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, Australia
Background/Purpose: Infiltration of monocyte-derived macrophages into the synovial tissue (ST) is a hallmark of rheumatoid arthritis (RA). These infiltrating cells lead to inflammation, local joint…
Abstract Number: 1946 • ACR Convergence 2021
Therapeutic Drug Monitoring Compared to Standard Infliximab Therapy in Patients with Immune-mediated Inflammatory Diseases: A Randomized Controlled Trial
Silje Watterdal Syversen¹, Guro Goll¹, Kristin Jørgensen², Marthe Brun¹, Øystein Sandanger³, Kristin Hammersbøen², Joseph Sexton¹, Inge Olsen³, Johanna Gehin⁴, David Warren³, Rolf Anton Klaasen³, Trude Bruun⁵, Maud Kristine Ljoså⁶, Anne Haugen⁷, Rune Njålla⁸, Brigitte Michelsen⁹, Camilla Zettel¹⁰, Yngvill Bragenes¹¹, Svanaug Skorpe¹², Eldri Strand¹³, Pawel Mielnik¹⁴, Cato Mørk¹⁵, Tore Kvien¹, Jørgen Jahnsen², Nils Bolstad¹⁶ and Espen Haavardsholm¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Lørenskog, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Oslo University Hospital, Lillehammer, Nepal, ⁵The University Hospital of North Norway, Tromsø, Norway, ⁶Dept. of Rheumatology, Ålesund Hospital, Ålesund, Norway, ⁷Østfold Hospital Trust, Moss, Norway, ⁸Nordland Hospital Trust, Bodø, Bodø, Norway, ⁹Hospital of Southern Norway Trust, Kristiansand, Norway, ¹⁰Betanien Hospital, Skien, Norway, ¹¹Vestre Viken Hospital Trust, Drammen, Norway, ¹²Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ¹³Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ¹⁴Førde Hospital Trust, Førde, Norway, ¹⁵Akershus Dermatology Center, Lørenskog, Norway, ¹⁶Oslo University Hospital, Radiumhospitalet, Oslo, Norway
Background/Purpose: Proactive therapeutic drug monitoring (TDM), a treatment strategy based on scheduled assessments of serum drug levels, has been proposed to optimize efficacy and safety…
Abstract Number: 0185 • ACR Convergence 2021
Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects
Silke Roedder¹, Emily Wendt², Chad Burris², Jonathan Nazareon², Grace Park³, Phil Pangilinan², Gianna Huang², Anubhav Mathur², James Taylor², Andrew Billin² and Franziska Matzkies⁴, ¹Gilead Sciences, Menlo Park, CA, ²Gilead Sciences, Foster City, CA, ³Gilead Sciences, Seattle, WA, ⁴Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of autoimmune diseases including Rheumatoid Arthritis (RA) and Lupus Erythematosus (LE). Immune complexes…
Abstract Number: 1013 • ACR Convergence 2021
SARS-CoV-2 Antibody Phenotype and Immune Gene Expression in Multi-system Inflammatory Syndrome in Children
Kate Webb¹, Thandeka Moyo-Gwete², Simon Mendelsohn³, Claire Butters⁴, Simone Richardson⁵, Heidi Facey-Thomas⁴, Debbie Abrahams⁴, Mashudu Madzivhandila⁵, Zanele Makhado⁵, Frances Ayres⁵, William Horsnell⁶, Neilia Manamela⁵, Richard Baguma³, Stanley Kimbung Mbandi³, Mzwandile Erasmus³, Thomas Scriba³, Liesl Zühlke⁷, Penny Moore⁵, George Kassiotis⁸ and Christiaan Scott⁴, ¹Paediatric Rheumatology University of Cape Town/ Francis Crick Institute, Cape Town, South Africa, ²National Institute of Communicable Diseases/University of Witwatersrand, Johannesburg, South Africa, ³South African TB vaccine initiative, IIDM, University of Cape Town, Cape Town, South Africa, ⁴Paediatric Rheumatology, University of Cape Town, Cape Town, South Africa, ⁵National Institute of Communicable Diseases/University of Witwatersrand, Cape Town, South Africa, ⁶University of Cape Town, Cape Town, South Africa, ⁷Paediatric Cardiology, University of Cape Town, Cape Town, South Africa, ⁸Retroviral Immunology, Francis Crick Institute, London, United Kingdom
Background/Purpose: Multi-system Inflammatory Syndrome in Children (MIS-C) is a severe disease that affects a small proportion of children exposed to Severe Acute Respiratory Syndrome Coronavirus…
Abstract Number: 0234 • ACR Convergence 2020
Characterization of Serious Infections with Upadacitinib in Patients with Rheumatoid Arthritis
Kevin Winthrop¹, Leonard Calabrese², Filip Van den Bosch³, Kunihiro Yamaoka⁴, Carlo Selmi⁵, Yanna Song⁶, Barbara Hendrickson⁷, Ivan Lagunes-Galindo⁸ and Iain McInnes⁹, ¹Oregon Health & Science University, Portland, OR, ²Cleveland Clinic, Cleveland, OH, ³Ghent University Hospital, Ghent, Belgium, ⁴Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ⁵Humanitas Research Hospital and Humanitas University, MIlan, Italy, ⁶AbbVie Inc., North Chicago,, IL, ⁷AbbVie, Inc, North Chicago, IL, ⁸AbbVie Inc., North Chicago, IL, ⁹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Upadacitinib (UPA) is a selective and reversible Janus kinase (JAK) inhibitor with an approved dose of 15 mg once daily (QD) for the treatment…
Abstract Number: 0772 • ACR Convergence 2020
Modification of THP-1 Cells with Malondialdehyde-Acetaldehyde Increases Cellular Calcium Load Rendering Cells Susceptible to Citrullination of Self-Proteins
Nozima Aripova¹, Michael Duryee¹, Xiarepati Tieliwaerdi¹, Xiaoting Jiang¹, Lynell Klassen², James O'Dell¹, Bryant England¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Univerisity of Nebraska Medical Center, Omaha, NE
Background/Purpose: The post translational modification of self-proteins with malondialdehyde-acetaldehyde (MAA) has been shown to alter protein function and antibodies to MAA are increased in both…
Abstract Number: 1440 • ACR Convergence 2020
The Myeloperoxidase (MPO) Anti-Neutrophilic Cytoplasmic Antibody (ANCA) Binding Epitope, MPO447-459 Induces CD4 T-cell Proliferation in Patients with MPO-ANCA-associated Vasculitis
Matthew Terrill¹, Hendrik Nel², Yassmin Musthaffa³, Wong Richard⁴, Ross Francis⁵, David Johnson⁵, Greg Keir⁶, David Gillis⁷ and Ranjeny Thomas⁸, ¹University of Queensland Diamantina Institute and Princess Alexandra Hospital, Rheumatology Department, Brisbane- Australia, Moffat beach, Queensland, Australia, ²University of Queensland Diamantina Institute, Brisbane, Queensland, Australia, ³University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Immunology Department, Princess Alexandra Hospital, Brisbane- Australia, Brisbane, Australia, ⁵Renal Department, Princess Alexandra Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁶Respiratory Department, Princess Alexandra Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁷Immunopathology Department, Royal Women’s and Children’s Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁸University of Queensland Diamantina Institute and Rheumatology Department, Princess Alexandra Hospital, Brisbane – Australia., Brisbane, Australia
Background/Purpose: In Myeloperoxidase (MPO) Anti Neutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis (MPO-AAV), murine and human studies suggest that the MPO435-465 region, which includes ANCA-binding MPO447-459, the…
Abstract Number: 1843 • ACR Convergence 2020
Integrated Efficacy of the AURORA 1 and AURA-LV Trials Confirms Voclosporin Rapid Proteinurea Reduction in the Presence of Low-Dose Steroids
Ellen M Ginzler¹, Joshua Kaplan², Laura Lisk³, Ray Federico⁴, Neil Solomons⁵ and Robert Huizinga⁵, ¹SUNY Downstate Health Sciences University, Brooklyn, ²Rutgers University, New Brunswick, NJ, ³Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ⁴Aurinia Pharmaceuticals, Inc., Victoria, Canada, ⁵Aurinia Pharmaceuticals, Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor (CNI) with a favorable metabolic profile and a consistent predictable dose response potentially eliminating the need for…
Abstract Number: 0237 • ACR Convergence 2020
Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis
Stanley Cohen¹, Ronald F Van Vollenhoven², Jeffrey Curtis³, Leonard Calabrese⁴, Cristiano AF Zerbini⁵, Yoshiya Tanaka⁶, Louis Bessette⁷, Casey Schlacher⁸, Tim Shaw⁹, John Liu⁹, Jeffrey Enejosa⁹, Yanna Song¹⁰ and Gerd Burmester¹¹, ¹Metroplex Clinical Research Center, Dallas, TX, ²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Cleveland Clinic, Cleveland, OH, ⁵Centro Paulista de Investigacao Clinica (CEPIC), Sao Paulo, Brazil, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Laval University, Quebec, Canada, ⁸AbbVie Inc., Lake Forest, IL, ⁹AbbVie Inc., North Chicago, IL, ¹⁰AbbVie Inc., North Chicago,, IL, ¹¹Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: The safety and efficacy of upadacitinib (UPA), an oral JAK inhibitor, was evaluated in the phase 3 SELECT clinical program, which included 5 randomized,…
Abstract Number: 0773 • ACR Convergence 2020
The Anti-carbamylated Fibrinogen Response in Rheumatoid Arthritis Targets a Specific Epitope on the γ-chain and Is Associated with a More Active Disease
Pauline Brevet¹, Manuel Freret¹, Pascal Rottenberg², Clément Guillou³, Thierry Lequerre⁴, Pascal Cosette⁵, Olivier Boyer² and Olivier Vittecoq⁶, ¹Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, Haute-Normandie, France, ²Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, France, ³CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, Haute-Normandie, France, ⁴Rheumatology, University Teaching Hospital, Rouen, France, ⁵CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, France, ⁶University Hospital of Rouen, Rouen, France
Background/Purpose: Anti-carbamylated protein autoantibodies (anti-CarP Abs) of IgG and/or IgA isotype have potential diagnostic and prognostic value Carbamylated Fetal Calf Serum (FCS) is the substrate…
Abstract Number: 1506 • ACR Convergence 2020
Correction of Sjögren’s Syndrome Fluid Secretion Deficits in Salivary Gland Acinar Cells by Aquaporin-1 Gene Transfer
Paola Perez¹, Blake Warner², Sandra Wainer¹, Youngmi Ji¹, Thomas Pranzatelli¹ and Jay Chiorini¹, ¹Nidcr, National Institute of Health, Bethesda, MD, ²National Institute of Dental and Craniofacial Research, Bethesda
Background/Purpose: The hallmark clinical complaints in Sjögren’s syndrome (SS) are dry mouth and dry eyes related to salivary and lacrimal glands dysfunction. Reduced salivation reflects…
Abstract Number: 1857 • ACR Convergence 2020
KIR3DL2 Is Not Overexpressed on CD4+ T Cells and NK Cells in Patients with Axial Spondyloarthritis csDMARD and bDMARD Naive
Guillaume Larid¹, Sophie Trijau¹, Clothilde Barral¹, Pierre Lafforgue¹ and Thao Pham², ¹Aix Marseille Univ, APHM, Rheumatology department, Marseille, France, ²Aix Marseille Univ, APHM, department of rheumatology, Marseille, France
Background/Purpose: Overexpression of KIR3DL2 on CD4+ T-cells and NK-cells has been reported in patients with ankylosing spondylitis (AS) HLAB27+. We aimed to 1) analyse KIR3DL2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].